CoChat

Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort

Open access
Mynarek, Martin, von Hoff, Katja, Pietsch, Torsten, Ottensmeier, Holger, Warmuth-Metz, Monika, Bison, Brigitte, Pfister, Stefan, Korshunov, Andrey, Sharma, Tanvi, Jaeger, Natalie, Ryzhova, Marina, Zheludkova, Olga, Golanov, Andrey, Rushing, Elisabeth Jane, Hasselblatt, Martin, Koch, Arend, Schüller, Ulrich, von Deimling, Andreas, Sahm, Felix, Sill, Martin, Riemenschneider, Markus J., Dohmen, Hildegard, Monoranu, Camelia Maria, Sommer, Clemens, Staszewski, Ori, Mawrin, Christian, Schittenhelm, Jens, Brück, Wolfgang, Filipski, Katharina, Hartmann, Christian, Meinhardt, Matthias, Pietschmann, Klaus, Haberler, Christine, Slavc, Irene, Gerber, Nicolas U., Grotzer, Michael, Benesch, Martin, Schlegel, Paul Gerhardt, Deinlein, Frank, von Bueren, André O., Friedrich, Carsten, Juhnke, Björn-Ole, Obrecht, Denise, Fleischhack, Gudrun, Kwiecien, Robert, Faldum, Andreas, Kortmann, Rolf Dieter, Kool, Marcel, Rutkowski, Stefan · 2020 · Journal of Clinical Oncology
Cited by 106

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

PURPOSE: The HIT-2000-BIS4 trial aimed to avoid highly detrimental craniospinal irradiation (CSI) in children < 4 years of age with nonmetastatic medulloblastoma by systemic chemotherapy, intraventricular methotrexate, and risk-adapted local radiotherapy. PATIENTS AND METHODS: From 2001-2011, 87 patients received systemic chemotherapy and intraventricular methotrexate. Until 2006, CSI was reserved for nonresponse or progression. After 2006, local radiotherapy was introduced for nonresponders or patients with classic medulloblastoma (CMB) or large-cell/anaplastic medulloblastoma (LCA). DNA methylation profiles of infantile sonic hedgehog-activated medulloblastoma (SHH-INF) were subdivided into iSHH-I and iSHH-II subtypes in the HIT-2000-BIS4 cohort and a validation cohort (n = 71) from the HIT group and Russia. RESULTS: Five years after diagnosis, patients with desmoplastic medulloblastoma (DMB) or medulloblastoma with extensive nodularity (MBEN; n = 42) had 93% progression-free survival (5y-PFS), 100% overall survival (5y-OS), and 93% CSI-free (5y-CSI-free) survival. Patients with CMB/LCA (n = 45) had 37% 5y-PFS, 62% 5y-OS, and 39% 5y-CSI-free survival. Local radiotherapy did not improve survival in patients with CMB/LCA. All DMB/MBEN assessed by DNA methylation profiling belonged to the SHH-INF subgroup. Group 3 patients (5y-PFS, 36%; n = 14) relapsed more frequently than the SHH-INF group (5y-PFS, 93%; n = 28) or group 4 patients (5y-PFS, 83%; n = 6; P < .001). SHH-INF split into iSHH-I and iSHH-II subtypes in HIT-2000-BIS4 and the validation cohort, without prognostic impact (5y-PFS: iSHH-I, 73%, v iSHH-II, 83%; P = .25; n = 99). Intelligence quotient (IQ) was significantly lower in patients after CSI (mean IQ, 90 [no radiotherapy], v 74 [CSI]; P = .012). CONCLUSION: Systemic chemotherapy and intraventricular methotrexate led to favorable survival in both iSHH subtypes of SHH-activated DMB/MBEN with acceptable neurotoxicity. Survival in patients with non-wingless (WNT)/non-SHH disease with CMB/LCA was not improved by local radiotherapy. Patients with group 4 disease had more favorable survival rates than those with group 3 medulloblastoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.19.03057

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 106

Metadata

Authors
Mynarek, M., von Hoff, K., Pietsch, T., Ottensmeier, H., Warmuth-Metz, M., Bison, B., Pfister, S., Korshunov, A., Sharma, T., Jaeger, N., Ryzhova, M., Zheludkova, O., Golanov, A., Rushing, E. J., Hasselblatt, M., Koch, A., Schüller, U., von Deimling, A., Sahm, F., Sill, M., Riemenschneider, M. J., Dohmen, H., Monoranu, C. M., Sommer, C., Staszewski, O., Mawrin, C., Schittenhelm, J., Brück, W., Filipski, K., Hartmann, C., Meinhardt, M., Pietschmann, K., Haberler, C., Slavc, I., Gerber, N. U., Grotzer, M., Benesch, M., Schlegel, P. G., Deinlein, F., von Bueren, A. O., Friedrich, C., Juhnke, B.-O., Obrecht, D., Fleischhack, G., Kwiecien, R., Faldum, A., Kortmann, R. D., Kool, M., & Rutkowski, S.
Venue
Journal of Clinical Oncology
Published
2020-06-20
Volume
38
Issue
18
Pages
2028-2040
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W3019206281
Cited by
106
References
2
FWCI
6.45
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.